Vimentin as a poor prognostic factor for triple-negative breast cancer

Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype

(2012) Hoiseon Jeong et al.   HISTOPATHOLOGY

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

(2012) Otto Metzger-Filho et al.   JOURNAL OF CLINICAL ONCOLOGY

Vimentin in cancer and its potential as a molecular target for cancer therapy

(2011) Arun Satelli et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects

(2011) Ismail Jatoi et al.   JOURNAL OF CLINICAL ONCOLOGY

Does vimentin help to delineate the so-called 'basal type breast cancer'?

(2009) Renata U Kusinska et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pattern of metastatic spread in triple-negative breast cancer

(2008) Rebecca Dent et al.   BREAST CANCER RESEARCH AND TREATMENT

Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype

(2008) D. Sarrio et al.   CANCER RESEARCH

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY